Kavya Keerthana: A Potentially Important Advance in Polycythemia Vera
Kavya Keerthana, Hematologist at Prime Health, shared a post on LinkedIn:
“A potentially important advance in Polycythemia Vera (PV).
In PV, excess red blood cells increase the risk of blood clots, stroke and heart attack.
For years, regular phlebotomy has been a cornerstone of treatment—but repeated blood removal can also lead to iron deficiency.
The FDA has approved rusfertide, a hepcidin mimetic that offers a different approach by regulating iron availability and reducing excessive red blood cell production.
In the Phase 3 VERIFY trial, 76.9 percent of patients receiving rusfertide achieved clinical response, with fewer phlebotomies and improvements in symptoms such as fatigue.
A fascinating shift in how we think about managing PV.”
Find more posts featuring Kavya Keerthana on Hemostasis Today.
-
Sep 3, 2026, 00:44Same goal, Different molecular strategy – Which FVIIIa Mimetic Gets There How? – RPTH Journal
-
Sep 3, 2026, 00:33Hannah Isles: Interesting Link between Aging, Serotonin, Platelets and COVID-19 Severity
-
Sep 3, 2026, 00:22Danny Hsu: Paradigm Shift in PE Management? – Unpacking the PRAGUE-26 Trial
-
Sep 3, 2026, 00:14Leonardo Roever: Antiphospholipid Antibodies Present in 19% of Ischemic Stroke Cases
-
Sep 3, 2026, 00:03Jochebed Adwoa Sutherland: First Reported Case of Breast Mondor’s Disease in a Patient Living with Sickle Cell
-
Sep 2, 2026, 23:50Shashank Joshi: Individualized vs. Standard BP Control Shows Similar 90-Day Outcomes
-
Sep 2, 2026, 18:26Strengthening Comprehensive Care for Inherited Bleeding Disorders in Ecuador – World Federation of Hemophilia
-
Sep 2, 2026, 18:24Zeeshan Ahmed Khattak: Managing Febrile Neutropenia in Hematology/Oncology and Transplant Patients
-
Sep 2, 2026, 18:22Mark Heyland: The Role of Thromboinflammation in Fracture Non-Union